Introduction {#Sec1}
============

Approximately 15--20 % of patients with breast cancers are diagnosed with TNBC, which lacks the expression of estrogen receptor (ER) and progesterone receptor (PgR) and gene amplification of *HER2* \[[@CR1]\]. The median survival of those with metastatic TNBC is poor, ranging 9--13.3 months in retrospective studies \[[@CR2], [@CR3]\]. There is a significant unmet clinical need to identify new therapeutic targets and treatment options for this patient population \[[@CR4]\].

Cell cycle checkpoints are mechanisms that arrest cell cycle progression in the presence of DNA damage to prevent the accumulation of mutations in normal cells but are exploited by cancer cells as a means of developing resistance to the cytotoxic effects of DNA damaging agents \[[@CR5]\]. The majority of TNBCs carry mutations in *TP53* \[[@CR6]--[@CR8]\], a gene that encodes the tumor suppressor protein p53 which is required for G1 checkpoint regulation in the presence of genotoxic stress \[[@CR9]\]. However, cells with deficient p53 rely on checkpoint kinase 1 (Chk1) to activate S- and G2-checkpoints for cell cycle arrest \[[@CR10]--[@CR12]\]. When Chk1 is inhibited, p53-deficient cancer cells undergo "mitotic catastrophe" and apoptosis in response to DNA damage \[[@CR5], [@CR10]--[@CR12]\]. Therefore, Chk1 inhibition in combination with DNA damaging agents is a potential synthetic lethal strategy to kill p53-deficient cells \[[@CR13]--[@CR16]\]. In addition, Chk1 transcript levels are found to be significantly elevated in TNBC compared to other breast cancer subtypes \[[@CR17], [@CR18]\], making it a feasible target in TNBC where *TP53* mutations also occur at a high frequency.

UCN-01 (7-hydroxystaurosporine) was the first Chk1 inhibitor introduced in the clinic, although it also inhibits several other serine-threonine protein kinases, including certain protein kinase C isoenzymes; Cdk2, 4, and 6; and PDK1 \[[@CR13], [@CR19], [@CR20]\]. Preclinical studies have shown that UCN-01 abrogates the S- and G2-checkpoints and enhances the cytotoxic effects of a variety of chemotherapeutic agents including SN-38, the active metabolite of camptothecin and irinotecan (a semisynthetic analog of camptothecin) in cancer cell lines including those of breast cancer \[[@CR21]--[@CR26]\]. Using human-in-mouse models of TNBC, we recently demonstrated that UCN-01 potentiated the cytotoxic effects of irinotecan in *TP53* deficient human TNBC cells \[[@CR27]\]. In our initial phase I study of UCN-01 and irinotecan in patients with refractory advanced solid tumor malignancies \[[@CR28]\], two partial responses were observed in women with TNBC. Both tumors were deficient for p53. Therefore, we hypothesized that UCN-01 and irinotecan would be an effective regimen in metastatic TNBC. In this trial, we determined the response rate, toxicity, and pharmacodynamic effects of irinotecan in combination with UCN-01 and correlated these findings with *TP53* mutation status, and breast cancer intrinsic subtype, in women with TNBC \[[@CR29]\].

Patient population and methods {#Sec2}
==============================

Patients {#Sec3}
--------

Eligible patients were at least 18 years of age with histologically confirmed breast cancer, negative for ER and PgR by immunohistochemistry and HER2 amplification by FISH and demonstrated an eastern cooperative oncology group (ECOG) performance status of 0--2. Patients had recurrent, measurable disease which was previously treated with an anthracycline and a taxane either in the adjuvant or metastatic setting and may have received up to three prior chemotherapeutic regimens for metastatic disease. Standard laboratory criteria were met and an oxygen saturation at least 90 % on room air at rest and after walking for 6 minutes was required. Prior chemotherapy or radiotherapy must have been completed at least 4 weeks prior to treatment. Patients with known sensitivity to UCN-01 or irinotecan, insulin-dependent diabetes mellitus or uncontrolled intercurrent illness, known diagnosis of Gilbert's disease, or chronic unconjugated hyperbilirubinemia were excluded. The Cancer Therapy Evaluation Program (P5582), Division of Cancer Treatment and Diagnosis, National Cancer Institute (CTEP, NCI) and the institutional review boards at both Washington University School of Medicine and the University of Virginia Health System approved this protocol. All patients provided written informed consent prior to study entry.

Treatment plan and study design {#Sec4}
-------------------------------

Patients received irinotecan (Camptosar^®^, Pfizer Inc., New York, NY) 100 or 125 mg/m^2^ depending on the *UGT1A1* genotype (patients with 7/7 allele were treated with 100 mg/m^2^, other patients 125 mg/m^2^), as a 90 min intravenous infusion on days 1, 8, 15, and 22 and UCN-01 (Kyowa Hakko Kogyo Co., Shizuoka, Japan and supplied by CTEP, NCI) as a 3 h continuous intravenous infusion on days 2 and 23 every 42 days. UCN-01 was administered at 70 mg/m^2^ day 2 and 35 mg/m^2^ day 23 and all subsequent doses. Dose modifications for irinotecan and UCN-01 included dose delays and reductions as previously described in the report on the phase I study of this combination \[[@CR28]\]. Toxicities were graded according to common terminology criteria for adverse events (CTCAE) version 4.0. Antitumor response was evaluated by physical examination and/or imaging at baseline and following every cycle. Responses were evaluated by RECIST 1.0 \[[@CR30]\].

Pharmacodynamic studies {#Sec5}
-----------------------

Western blot analyses of peripheral blood mononuclear cells (PBMC) were collected at baseline, 24 h post irinotecan but prior to UCN-01 (day 2), 24 h post UCN-01 (day 3), and on day 8 prior to the second irinotecan administration during cycle 1 for western blot analyses of phosphorylated ribosomal protein S6 (pS6), S6, pAKT^S473^, AKT, pGSK3β, and GSK3β. The procedures of sample processing, western blot, and quantification of pS6 to S6 ratio were described in detail previously \[[@CR28]\]. The primary antibodies for pS6^S240/244^, S6, pAKT^S473^, pGSK3β, and GSK3β were from Cell Signaling Technology, Inc., Danver, MA; and the primary antibodies for AKT and actin were from Santa Cruz Biotechnology, Delaware, CA, and Sigma Chemical Co., St. Louis, MO, respectively.

Immunofluorescent (IF) staining of tumors {#Sec6}
-----------------------------------------

Serial tumor biopsies of chest wall recurrences from five consented patients (patients 1, 3, 4, 6, and 11) were obtained at baseline, 24 h post irinotecan but prior to UCN-01 (day 2), 24 h post UCN-01 treatment (day 3) for immunofluorescent staining (IF) of pS6, cleaved caspase 3, phistone H3, pChk1^S296^, and γH2AX. Tumor biopsies were fixed in formalin, processed for hematoxylin and eosin staining, and reviewed by a pathologist to confirm cellularity prior to IF staining studies. Sample processing, antibodies and IF staining were performed as previously described \[[@CR27]\]. The primary antibodies were pS6^S240/244^ (Cell Signaling Technology, Inc.), pChk1^S296^ (Epitomics, Inc., Burlingame, CA), cleaved caspase 3 (Cell Signaling Technology), phistone H3^S28^ (1:1,000, Sigma-Aldrich Co.), and γH2AX^S139^ (Cell Signaling Technology, Inc.). Tumor cells staining positive for phistone H3 and/or γH2AX or cleaved caspase 3 were counted in five randomly selected fields per tumor at 400X magnification. Between 225 and 1700 tumor cells were counted.

DNA extraction and *TP53* sequencing of tumors {#Sec7}
----------------------------------------------

Tumor genomic DNA was isolated from 15 patients with metastatic breast cancer and analyzed for *TP53* mutation by direct nucleotide sequencing of polymerase chain products of exons 4--9 as described \[[@CR28]\].

RNA preparation, RT-PCR, and assignment of molecular subtyping of tumors {#Sec8}
------------------------------------------------------------------------

The details on RNA extraction, RT-PCR, and PAM50 Breast Cancer Intrinsic Classifier™ (PAM50, ARUP Laboratories, Salt Lake City, Utah) molecular subtyping assignment were according to previously published methods \[[@CR31]\].

Statistical considerations {#Sec9}
--------------------------

The primary endpoints for the study were the evaluation of efficacy including the overall response rate defined as complete response and partial response (CR + PR), clinical benefit rate \[CR + PR + SD (stable disease)\], time to treatment failure (TTF), overall survival (OS), and the evaluation of the side effect profile of this combination. The study was designed to accrue a minimum of 20 patients to have adequate precision to estimate the true overall response rate. Precision was defined by the width of a 95 % exact binomial confidence interval with an expected observed rate of at least 5/20 or a minimum lower bound of 8 %.

OS was measured from start of treatment date until date of death from any cause or last follow, whichever occurred first. TTF was measured from start of treatment date until date of treatment discontinuation due to adverse events; physician discretion; patient withdrawal; progression; death from any cause; or last follow up, whichever occurred first.

Adverse events were tabulated by severity and frequency of events. Point estimates and 95 % exact binomial confidence intervals were calculated for all response rates. The Kaplan--Meier product limit estimator was used to estimate time to event distributions which included OS and TTF. The logrank test was used to test for differences in time to event distributions with a two-sided test.

Graphical methods were used to display pharmacodynamic measures, and analyses were considered exploratory. Repeated measure models were used to estimate the pattern of changes over time for log transformed pS6 and S6 ratio measures.

Results {#Sec10}
=======

Patient characteristics {#Sec11}
-----------------------

Between January 2007 and November 2010, 25 patients with metastatic TNBC were enrolled. Patient characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Patients had prior treatment with an anthracycline and a taxane and the median number of prior regimens was 3 (ranges 1--4).Table 1Patient characteristicsCharacteristicNo. of patients (*n* = 25)Age (years) Mean (range)53 (37--78)Race Black or African American12 Caucasian13ECOG performance status 011 112 22Prior chemotherapy Mean no. of regimens (range)3 (1--4)*ECOG* Eastern cooperative oncology group

Toxicity {#Sec12}
--------

Twenty of 25 patients completed at least one cycle of treatment (range 1--6). All 25 patients were evaluated for treatment-related adverse events (Table [2](#Tab2){ref-type="table"}). The most common hematological toxicities were neutropenia and anemia. Only 1 patient developed febrile neutropenia. The most common non-hematological toxicities were gastrointestinal toxicities including nausea/vomiting and diarrhea. Two patients developed colitis while on study (1 due to *Clostridium difficile*). Laboratory abnormalities were observed and were most often associated with gastrointestinal toxicities. Two treatment-related elevations in AST/ALT were observed. One patient with baseline grade 1 AST/ALT and liver metastases developed a grade 2 fever, grade 3 hyperglycemia, and transient grade 3 ALT/AST elevation within 24 h following cycle 1, day 2 UCN-01 administration. The patient's serum levels of ALT/AST decreased to baseline level (grade 1) within 2 days and she completed the cycle without further transaminase elevations. The other patient developed a grade 3 ALT following cycle 1 week 1 and grade 4 ALT/grade 3 AST during cycle 2 week 4. As per protocol, this patient was removed from study due to grade 4 ALT. This patient's transaminase elevations resolved to grade 1 2 weeks after the last treatment. Several patients had toxicities related to UCN-01. Two patients experienced hypoxia (grade 2 and grade 3, respectively), and five patients experienced grade 1 or 2 hypotension during the UCN-01 infusion that responded to intravenous fluid. As per protocol, the patient with grade 3 hypoxia, associated with grade 2 hypotension, was removed from study. Hyperglycemia occurred in over half of the patients, with grade 3 or 4 in five patients.Table 2Incidence of adverse eventsGrade of adverse event(*n* = 25)1234Blood and lymphatic system disorders Anemia51222 Febrile neutropenia1 Neutrophil count decreased3631 Platelet count decreased42Gastrointestinal disorders Abdominal pain711 Colitis11 Diarrhea843 Nausea/vomiting1343General disorders and administration site conditions Chills4 Fatigue15 Fever11Investigations Alanine aminotransferase increased411 Alkaline phosphatase increased131 Aspartate aminotransferase increased1220 Weight loss62Metabolism and nutrition disorders Anorexia41 Dehydration4 Hypercalcemia3 Hyperglycemia1741 Hypoalbuminemia42 Hypocalcemia24 Hypokalemia64 Hyponatremia6 Hypophosphatemia11Nervous system disorders Dizziness51 Headache31UCN-01 Infusion-Related Hypotension14 Hypoxia11

Efficacy {#Sec13}
--------

Among the 25 patients enrolled, only 22 were evaluated for response as one withdrew consent and two went off study during cycle 1 due to toxicities, one due to elevated transaminases and the other as a result of hypoxia during the UCN-01 infusion (Table [3](#Tab3){ref-type="table"}). No complete responses were observed. One PR lasting 24 weeks occurred in a patient (patient 15) with liver and lung metastasis. This patient was previously treated with neoadjuvant FEC-T (5-Fluorouracil, epirubicin, cyclophosphamide followed by docetaxel) at initial diagnosis and, at disease progression, with capecitabine followed by paclitaxel and bevacizumab. Tumor from this patient was found to be basal-like, and carry a *TP53* mutation (Table [4](#Tab4){ref-type="table"}). The overall response rate (CR + PR) was 1 in 25 \[4, 95 % CI (0, 20 %)\]. Two patients had prolonged disease stabilization that lasted for 37 and 28 weeks, respectively. The clinical benefit rate (CR + PR + SD \> 6 months) was 3 in 25 \[12, 95 % CI (3, 31 %)\]. The median TTF and OS were 1.7 months, 95 % CI (1.2, 2.6 months) and 11.3 months, 95 % CI (3.8, 19.0 months), respectively, as shown in Fig. [1](#Fig1){ref-type="fig"}a, b. The study did not meet the pre-defined efficacy criteria for further evaluation.Table 3Response summaryBest Response*N* (%)Partial response1 (4)Stable disease8 (32)2 \> 6 months5 \> 3 months8 \> 2 monthsProgressive disease13 (52)Not evaluable^a^3 (12)^a^1 withdrew consent and 2 went off study during cycle 1 due to toxicityTable 4Tumor molecular subtypes and *TP53* statusPatient IDBest responseTTF (months)OS (months)Molecular subtypeTP53 sequencing**1PD1.82.0Basal-likeL139N**2PD1.53.8Basal-likeP151S3SD8.620.3HER2-enrichedW**4PD3.714.5Basal-likeW**5PD1.014.7Basal-likeInsertion^a^**6PD1.623.9N/AW**7SD6.549.5Basal-likeW8SD4.010.6Basal-likeN/A**11SD2.63.2Luminal BDeletion**^**b**^12SD2.58.8Basal-like/HER2 enrichedR306X17PR6.17.3Basal-likeR273C19PD1.32.9Luminal BW20PD1.211.3Basal-likeR273C22PD1.219.0HER2-enrichedW23SD2.820.6Basal-likeW25PD1.22.3Basal-likeR273H*Bold* serial tumor biopsies at baseline, day 2 (24 h after irinotecan) and day 3 (24 h after UCN-01)*PR* partial response, *SD* stable disease, *PD* progressive disease, *W* wild type^a^11554_11555het_insTTTCC^b^11532_11548delAAAACTACCAGGGCAGFig. 1Patient outcome. Kaplan--Meier survival curves on time to treatment failure (TTF) (**a**) and OS (**b**) for all patients and Kaplan--Meier survival curves on TTF (**c**) and OS (**d**) by tumor *TP53* mutation status

Pharmacodynamic studies {#Sec14}
-----------------------

PBMCs were collected to evaluate the bioavailability of UCN-01 over time. Since UCN-01 inhibits PDK1, treatment with UCN-01 was expected to reduce levels of pS6, pAKT, and pGSK3β \[[@CR32], [@CR33]\]. The levels of the phosphorylated S6, AKT, and GSK3β were decreased 24 h after UCN-01 on day 3, but returned to baseline on day 8 in most patients (*n* = 24, data not shown). Representative western blots pre- and post-therapy are shown for two patients (Fig. [2](#Fig2){ref-type="fig"}a). The ratio of pS6 to S6 was quantified at baseline (*n* = 24), day 1 (*n* = 24), day 3 (*n* = 22), and day 8 (*n* = 20) (Fig. [2](#Fig2){ref-type="fig"}b). Compared to baseline, the ratio of pS6 to S6 was decreased significantly (*p* \< 0.001) 24 h after UCN-01 on day 3, but not significantly different on day 8, indicating that UCN-01 activity was not present by day 8.Fig. 2Pharmacodynamic effects of UCN-01 on PBMC (**a**, **b**) and tumor tissue (**c**--**h**). PBMC were collected at baseline (BL), 24 h post irinotecan but prior to UCN-01 on day 2 (D2), 24 h post UCN-01 on day 3 (D3), and on day 8 (D8) prior to the second irinotecan treatment during cycle 1. PBMC were lysed and analyzed by western blotting with antibodies specific for total and phosphorylated forms of S6 ribosomal protein (S6), AKT, and GSK3ß with actin as a loading control. Representative western blots from two patients (4 and 11) are shown (**a**). The ratio of pS6 to total S6 protein level was plotted at each time point (**b**). Optional serial tumor biopsies were collected before study drug therapy at baseline (BL), 24 h post irinotecan but prior to UCN-01 on day 2 (D2), and 24 h post UCN-01 on day 3 (D3) from 4 patients (1, 4, 6, and 11). Representative immunofluorescent (IF) staining images on tumors from patient 11 are shown in (**c**). The quantitation of the IF analysis on the γH2AX (**d**), pChk1^S296^ (**e**), phistone H3 (**f**), cleaved caspase 3 (**g**), and pS6 (**h**), for each patient is shown in the lower panels. CC3 cleaved caspase 3

To evaluate the molecular effects of UCN-01, serial tumor biopsies were collected at three time points including baseline, day 2 (24 h post irinotecan), and day 3 (24 h post UCN-01) in five patients (1, 3, 4, 6, and 11) with chest wall recurrences. Tumors from patients 1 and 11 were mutant for *TP53*, while those from patients 3, 4, and 6 were wild type for *TP53* (Table [4](#Tab4){ref-type="table"}). Tumor biopsies from patient 3 were not submitted for further analysis because there were no tumor cells in the baseline sample. Immunostaining of γH2AX (marker for double strand DNA breaks), pChk1^S296^ (marker of Chk1 activation), phistone H3 (marker for mitosis), cleaved caspase 3 (CC3) (marker for apoptosis), and pS6 were performed. As expected from treatment with irinotecan, there was an increase in double strand DNA breaks (↑ γH2AX) (Fig. [2](#Fig2){ref-type="fig"}c, d) and activation of Chk1 (↑ pChk1^S296^) (Fig. [2](#Fig2){ref-type="fig"}c, e) in all tumors on day 2 biopsy (representative staining from patient 11's tumor). phistone H3 staining was low at baseline (1--2 %); therefore, the anticipated further reduction of phistone H3 due to cell cycle arrest from irinotecan was difficult to demonstrate (Fig. [2](#Fig2){ref-type="fig"}c, f). Despite the anticipated pharmacodynamic effects of irinotecan, there was little induction of apoptosis on day 2 (Fig. [2](#Fig2){ref-type="fig"}c, g). Following UCN-01 therapy, pS6 was reduced in all tumors (Fig. [2](#Fig2){ref-type="fig"}c, h). However, loss of Chk1^S296^ was only observed in tumors from patients 6 (*TP53* WT (wild type)) and 11 (*TP53* deletion) (Fig. [2](#Fig2){ref-type="fig"}c, e). Tumor from patient 11, which had a deletion in *TP53*, demonstrated the most dramatic increase in apoptosis with close to 10 % of tumor cells stained positive for cleaved caspase 3 on day 3 (Fig. [2](#Fig2){ref-type="fig"}g). The same tumor demonstrated a slight increase in phistone H3 (Fig [2](#Fig2){ref-type="fig"}f) and an increase in γH2AX (Fig. [2](#Fig2){ref-type="fig"}d) following combination therapy, suggesting cell cycle abrogation and enhanced DNA damage from the addition of UCN-01. The patient had a best response of stable disease and a TTF of 2.6 months. Interestingly, tumor from patient 6, which was WT (wild type) for *TP53*, showed the most dramatic increase in phistone H3 (Fig. [2](#Fig2){ref-type="fig"}f) following UCN-01, suggesting cell cycle abrogation, but this patient had a best response of PD and a TTF of 1.6 months on study, indicating ineffective therapy.

In summary, data on pChk1^S296^ indicated an inconsistent effect of UCN-01 on Chk1, with one (patient 11) of two *TP53* mutant tumors demonstrating the anticipated cell cycle pharmacodynamic effect (loss of pS296) of UCN-01. However, given that active Chk1 (p296-phosphorylated form) is targeted for ubiquitin-mediated proteolysis, there may have been less total Chk1 in this tumor sample \[[@CR34]--[@CR36]\].

Predictive biomarker analysis {#Sec15}
-----------------------------

To investigate the molecular characteristics of the TNBC and their potential predictive value in prognosis and therapeutic response, tumor specimens for *TP53* mutation and molecular subtype by PAM50 were analyzed (Table [4](#Tab4){ref-type="table"}). Among the 25 patients enrolled, one withdrew consent and a specimen was not requested, three were without available archival tumor specimens, and five had archival tumor specimens with limited cellularity, and one each had poor quality DNA and RNA, respectively. Among the 15 patients with sufficient specimens for PAM50 analysis, there were ten basal-like, one basal/HER2-enriched, two HER2-enriched, and two luminal B. Among the 15 patients with sufficient tumors for analysis, eight (53 %) carried mutations in *TP53*. In this limited dataset, there was no significant difference in TTF between the two populations (Fig. [1](#Fig1){ref-type="fig"}c), but a significantly worse OS was observed in patients with mutations in *TP53*. The median OS was 5.5 (95 % CI: 2, 11) months and 20.3 (95 % CI: 3, 24) months in patients with and without *TP53* mutation (*p* = 0.004), respectively (Fig. [1](#Fig1){ref-type="fig"}d).

Discussion {#Sec16}
==========

Irinotecan administered weekly as a single agent has been shown to induce an overall response rate of 5--23 % in unselected patients with metastatic breast cancers resistant to anthracycline and/or taxane \[[@CR37], [@CR38]\]. In this study, women with resistant TNBC had previously received both an anthracycline and a taxane and had a median of 3 chemotherapy regimens. The overall response rate to irinotecan in combination with UCN-01 was 4 % and TTF was 1.7 months in our study. Given the low response rate observed, UCN-01, when administered on a day 2 and 23 schedule in combination with weekly irinotecan (days 1, 8, 15, 22), did not appear to potentiate the cytotoxic effects of irinotecan.

The pharmacodynamics studies on serially collected PBMC and tumor biopsies revealed limited bioavailability of UCN-01 to tissue, likely as a result of the high affinity binding of this agent to the α1-acid glycoprotein (AAG) \[[@CR28], [@CR39]--[@CR41]\]. Despite the higher dose of UCN-01 on day 2 compared to subsequent doses, the initial suppression of pS6 in PBMC on day 3 was no longer detected by day 8, a similar finding from our initial phase I study of this combination \[[@CR28]\]. In addition, the inhibitory effect of UCN-01 on tumor tissue Chk1, which was activated by irinotecan in all tumors on day 2, was inconsistent although pS6 was inhibited on day 3. These data support the notion that UCN-01 was not able to achieve the desired Chk1 inhibition, likely due to the limited tissue bioavailability with the current dosing and scheduling. Interestingly, patient 11's tumor, which had a deletion in *TP53* and a reduction in pChk1 following UCN-01, had a dramatic increase in apoptosis following UCN-01, indicating inhibition of cell cycle checkpoint and potentiation of the cytotoxic effects of irinotecan. As anticipated, enhanced apoptosis was not observed in the tumor from patient 6, which was wild type for *TP53*, although there was also a reduction in pChk1 following UCN-01 in this tumor. Further studies of Chk1 inhibitors with improved pharmacokinetic properties and selectivity for Chk1 are needed \[[@CR13]\].

Analysis of γH2AX, pChk1, and cleaved caspase 3 on serial biopsies obtained from four patients at baseline and on day 2 after irinotecan indicated that although irinotecan induced anticipated DNA damage and activation of checkpoint pathways, the effect on apoptosis was minimal. The failure to induce cell death following DNA damage indicates mechanisms in place in these tumors to counteract the apoptotic effect of irinotecan, and these resistance mechanisms remain to be elucidated. These data highlight the need for a better understanding of treatment resistance to chemotherapy for TNBC.

As reported in the literature \[[@CR42], [@CR43]\], we observed a significant heterogeneity in TNBC in this study. Most of the tumors were basal-like by PAM50 breast cancer molecular subtyping; other subtypes included HER2-enriched and luminal B. The frequency of each subtype is consistent with previous reports \[[@CR43]--[@CR45]\]. Despite its small sample size, this study demonstrates that *TP53* mutation is a robust predictor of worse clinical outcome in patients with metastatic TNBC. In a single institution small retrospective study of 135 patients with early stage breast cancer, including 32 patients with TNBC treated with adjuvant anthracycline-based chemotherapy, p53 status assessed by IHC was strongly predictive of relapse free survival and OS only in the TNBC cases \[[@CR46]\]. Similar findings were obtained in another retrospective study that used IHC analysis \[[@CR47]\]. Our study provides important confirmatory evidence that *TP53* mutation is a predictor of worse outcome in the anthracycline and taxane resistant metastatic TNBC patient population. The significant difference in outcome indicates a need to stratify patients based on *TP53* status in the design of clinical trials in patients with metastatic TNBC. Though we were not able to obtain specimens on all patients, the biomarker analyses of PBMC, archival tumor, and biopsy specimens that were obtained have provided important insights into the biology of TNBC when treated with UCN-01 in combination with irinotecan.

Conclusions {#Sec17}
===========

In this trial, we examined the therapeutic potential of UCN-01, the first identified Chk1 inhibitor, in combination with irinotecan, in patients with metastatic TNBC. Although the clinical activity was unimpressive most likely due to the pharmacokinetic property of UCN-01, we developed effective pharmacodynamic markers to evaluate target inhibition for this class of agents. Our data indicated that effective Chk1 inhibition could enhance chemotherapy-induced apoptosis in *TP53* mutant tumors. Furthermore, we demonstrated that TNBC is molecularly heterogeneous and *TP53* mutant TNBC was associated with a particularly poor survival, indicating a need to stratify patient populations in clinical trials. These results provide a foundation for future trials of Chk1 inhibitors in TNBC.
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